CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapyJohannes Sam, Pablo Umaña, Martin Lechmann et al.|Blood|2024Cited by 40
Abstract 1235: Impact of anti-CD3 and tumor-target binder affinities on <i>in-vitro</i> potency, <i>in-vivo</i> efficacy, and cytokine releaseOmar Abdelmotaleb, Christian Klein, Anneliese Schneider et al.|Cancer Research|2024Cited by 1
P-02.04 Developing T cell bispecific antibodies with reduced-affinity anti-CD3 binders for a potent, efficacious, and low-cytokine responseOmar Abdelmotaleb, Anina Schneider, C Klein et al.|Poster presentations|2025Cited by 0
An alternative nonclinical approach to support the first-in-human clinical trial of a T-cell bispecific targeting EGFRvIIIElisabeth Husar, Antje‐Christine Walz, Afsaneh Abdolzade‐Bavil et al.|Journal of Pharmaceutical Sciences|2025Cited by 0